Clinical characterisation of 29 neurofibromatosis type-1 patients with molecularly ascertained 1.4 Mb type-1 NF1 deletions
The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
Background: Large deletions of the NF1 gene region occur in ∼5% of patients with neurofibromatosis type-1 (NF1) and are associated with particularly severe manifestations of the disease. However, until now, the genotype–phenotype relationship has not been comprehensively studied in patients harbouring large NF1 gene deletions of comparable extent (giving rise to haploinsufficiency of the same genes). Method: We have performed the most comprehensive clinical/neuropsychological characterisation so far undertaken in NF1 deletion patients, involving 29 patients with precisely determined type-1 NF1 (1.4 Mb) deletions. Results: Novel clinical features found to be associated with type-1 NF1 deletions included pes cavus (17% of patients), bone cysts (50%), attention deficit (73%), muscular hypotonia (45%) and speech difficulties (48%). Type-1 NF1 deletions were found to be disproportionately associated with facial dysmorphic features (90% of patients), tall stature (46%), large hands and feet (46%), scoliosis (43%), joint hyperflexibility (72%), delayed cognitive development and/or learning disabilities (93%) and mental retardation (IQ<70; 38%), as compared with the general NF1 patient population. Significantly increased frequencies (relative to the general NF1 population) of plexiform neurofibromas (76%), subcutaneous neurofibromas (76%), spinal neurofibromas (64%) and MPNSTs (21%) were also noted in the type-1 deletion patients. Further, 50% of the adult patients exhibited a very high burden of cutaneous neurofibromas (N≥1000). Conclusion: These findings emphasise the importance of deletion analysis in NF1 since frequent monitoring of tumour presence and growth could potentiate early surgical intervention thereby improving patient survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Malignant peripheral nerve sheath tumours in neurofibromatosis 1
Evans, D. G. R., Baser, M. E., McGaughran, J., Sharif, S., Howard, E., & Moran, A. (2002) · Journal of Medical Genetics · doi:10.1136/jmg.39.5.311 · Cited by 1,282 · cited 1×
“deletions. Thus, whereas the lifetime risk of an MPNST in all NF1 individuals is 8–13%,”
BackgroundGuidelines for the diagnosis and management of individuals with neurofibromatosis 1
Ferner, R. E., Huson, S. M., Thomas, N., Moss, C., Willshaw, H., Evans, D. G., Upadhyaya, M., Towers, R., Gleeson, M., Steiger, C., et al. (2007) · Journal of Medical Genetics · doi:10.1136/jmg.2006.045906 · Cited by 1,053 · cited 1×
“deletions. The prevalence of PNF in the general NF1 population has been estimated by CT and MRI imaging to be 43–50%.”
MethodNeurofibromatosis, Phenotype, Natural History, and Pathogenesis
Riccardi, V. M., & Smirniotopoulos, J. (1992) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199211000-00009 · Cited by 893
International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis.
Ferner, R. E., & Gutmann, D. H. (2002) · PubMed · Cited by 705
VON RECKLINGHAUSEN NEUROFIBROMATOSIS: A CLINICAL AND POPULATION STUDY IN SOUTH-EAST WALES
HUSON, S. M., HARPER, P. S., & COMPSTON, D. A. S. (1988) · Brain · doi:10.1093/brain/111.6.1355 · Cited by 686 · cited 1×
“Macrocephaly, measured as occipital-frontal circumference at or above the 97th percentile, was ascertained in 39% of patients (additional table 7). Since macrocephaly is observed in 29–45% of all individuals with NF1,”
BackgroundThe nature and frequency of cognitive deficits in children with neurofibromatosis type 1
Hyman, S. L., Shores, A., & North, K. N. (2005) · Neurology · doi:10.1212/01.wnl.0000179303.72345.ce · Cited by 637
Listernick, R., Louis, D. N., Packer, R. J., & Gutmann, D. H. (1997) · Annals of Neurology · doi:10.1002/ana.410410204 · Cited by 478
Cardiovascular disease in neurofibromatosis 1: Report of the NF1 Cardiovascular Task Force
Friedman, J. M., Arbiser, J., Epstein, J. A., Gutmann, D. H., Huot, S. J., Lin, A. E., Mcmanus, B., & Korf, B. R. (2002) · Genetics in Medicine · doi:10.1097/00125817-200205000-00002 · Cited by 402
von Recklinghausen Neurofibromatosis
Lewis, R. A., Gerson, L. P., Axelson, K. A., Riccardi, V. M., & Whitford, R. P. (1984) · Ophthalmology · doi:10.1016/s0161-6420(84)34217-8 · Cited by 354
Association between benign and malignant peripheral nerve sheath tumors in NF1
Tucker, T., Wolkenstein, P., Revuz, J., Zeller, J., & Friedman, J. M. (2005) · Neurology · doi:10.1212/01.wnl.0000168830.79997.13 · Cited by 311 · cited 3×
“) because subcutaneous neurofibromas were ascertained in only 48% of 468 NF1 patients unselected by NF1 mutation type and hence probably reflecting the general NF1 population.(47) Cutaneous neurofibromas were observed in 86% of our 29 type-1 deletion patients.”
BackgroundInfluential
Cited by
PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies
De Raedt, T., Beert, E., Pasmant, E., Luscan, A., Brems, H., Ortonne, N., Helin, K., Hornick, J. L., Mautner, V., Kehrer-Sawatzki, H., et al. (2014) · Nature · doi:10.1038/nature13561 · Cited by 461
Self-citationThe NF1 somatic mutational landscape in sporadic human cancers
Philpott, C., Tovell, H., Frayling, I. M., Cooper, D. N., & Upadhyaya, M. (2017) · Human Genomics · doi:10.1186/s40246-017-0109-3 · Cited by 303
Self-citationEmerging genotype–phenotype relationships in patients with large NF1 deletions
Kehrer-Sawatzki, H., Mautner, V.-F., & Cooper, D. N. (2017) · Human Genetics · doi:10.1007/s00439-017-1766-y · Cited by 206
“However, even within this group of patients that are hemizygous for the same number of genes, some variability in expression of the clinical symptoms has been detected (Mautner et al. 2010).”
BackgroundInfluentialSelf-citationStewart, D. R., Korf, B. R., Nathanson, K. L., Stevenson, D. A., & Yohay, K. (2018) · Genetics in Medicine · doi:10.1038/gim.2018.28 · Cited by 202
Rojnueangnit, K., Xie, J., Gomes, A., Sharp, A., Callens, T., Chen, Y., Liu, Y., Cochran, M., Abbott, M., Atkin, J., et al. (2015) · Human Mutation · doi:10.1002/humu.22832 · Cited by 188
Neurofibromatosis type 1-associated tumours: Their somatic mutational spectrum and pathogenesis
Spyk, S., Thomas, N., Cooper, D. N., & Upadhyaya, M. (2011) · Human Genomics · doi:10.1186/1479-7364-5-6-623 · Cited by 164
Self-citationMartin, S., Wolters, P. L., Toledo‐Tamula, M. A., Schmitt, S. N., Baldwin, A., Starosta, A., Gillespie, A., & Widemann, B. (2016) · American Journal of Medical Genetics, Part A · doi:10.1002/ajmg.a.37623 · Cited by 61
“Individuals with these tumors can have disfigurement, significant functional deficits [Mautner et al., 2010], and reduced activities of daily living [Martin et al., 2014].”
Metadata
- Authors
- Mautner, V.-F., Kluwe, L., Friedrich, R. E., Roehl, A. C., Bammert, S., Högel, J., Spöri, H., Cooper, D. N., & Kehrer-Sawatzki, H.
- Venue
- Journal of Medical Genetics
- Publisher
- BMJ
- Published
- 2010-06-12
- Volume
- 47
- Issue
- 9
- Pages
- 623-630
- ISSN
- 0022-2593 (ISSN-L)
- 1468-6244
- OpenAlex
- W2085699375
- Cited by
- 173
- References
- 50
- FWCI
- 6.77
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.